The role of afatinib in the management of non-small cell lung carcinoma.

about

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.

P2860

Q34260686-CAE70F37-8790-43C2-8F98-E529F5C814F0 Q38252486-54407DC3-8311-431E-B9F6-F13E95996E92

P2860

The role of afatinib in the management of non-small cell lung carcinoma.

Item

http://www.wikidata.org/entity/Q38132282

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The role of afatinib in the management of non-small cell lung carcinoma.

@en

type

Item

label

The role of afatinib in the management of non-small cell lung carcinoma.

@en

prefLabel

The role of afatinib in the management of non-small cell lung carcinoma.

@en

P1476

The role of afatinib in the management of non-small cell lung carcinoma.

@en

P2093

Sanjay Popat

http://www.w3.org/2001/XMLSchema#string

Timothy A Yap

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Cancer. Addiction to oncogenes--the Achilles heal of cancer

P304

1529-1539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.832755

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23985030

http://www.w3.org/2001/XMLSchema#string

The role of afatinib in the management of non-small cell lung carcinoma.

about

P2860

P2860

The role of afatinib in the management of non-small cell lung carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698